Remedium Lifecare Ltd
REMLIFERemedium Lifecare Ltd
REMLIFE
Price Chart
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 13.50 | 5.81 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 49.70 | 6.31 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
0
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 4.26 | 1.43 | 0.37 | 0.25 | 2.89 | 90.03 | 504.79 | 509.84 | 4,062.79 | 3,365.17 | ||||||||||
Raw Materials | 3.65 | 0.71 | 0.14 | 0.00 | 0.00 | 0.00 | 0.00 | 417.30 | 4,127.29 | 3,320.93 | ||||||||||
| Power & Fuel Cost | 0.08 | 0.08 | 0.02 | 0.00 | 0.05 | 0.07 | 0.09 | 0.06 | 0.06 | |||||||||||
| Employee Cost | 0.05 | 0.04 | 0.13 | 0.04 | 0.18 | 0.19 | 0.21 | 0.55 | 0.40 | |||||||||||
| Selling & Administrative Expenses | 0.20 | 0.13 | 0.05 | 0.00 | 0.47 | 1.09 | 3.76 | 6.46 | 4.95 | |||||||||||
| Operating & Other expenses | 0.25 | 0.47 | 0.01 | 0.19 | 1.79 | 87.96 | 498.91 | 77.46 | -125.20 | |||||||||||
EBITDA | 0.03 | 0.00 | 0.02 | 0.02 | 0.40 | 0.72 | 1.82 | 8.01 | 55.29 | 44.24 | ||||||||||
| Depreciation/Amortization | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.06 | 0.07 | 0.15 | 0.06 | 0.04 | ||||||||||
| PBIT | 0.02 | 0.00 | 0.02 | 0.02 | 0.39 | 0.66 | 1.75 | 7.86 | 55.23 | 44.20 | ||||||||||
| Interest & Other Items | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.23 | 0.45 | 4.78 | 6.69 | ||||||||||
| PBT | 0.01 | 0.00 | 0.02 | 0.02 | 0.38 | 0.64 | 1.52 | 7.41 | 50.45 | 37.51 | ||||||||||
| Taxes & Other Items | 0.00 | 0.00 | 0.00 | 0.02 | 0.09 | 0.17 | 0.45 | 1.97 | 17.72 | 19.03 | ||||||||||
| Net Income | 0.01 | 0.00 | 0.02 | -0.00 | 0.29 | 0.47 | 1.07 | 5.44 | 32.73 | 18.48 | ||||||||||
| EPS | 0.00 | 0.00 | 0.00 | -0.00 | 0.01 | 0.01 | 0.03 | 0.13 | 1.48 | 4.58 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Remedium Lifecare Ltd | 7.62 | 5.81 | — |
| Sun Pharmaceutical Industries Ltd | 44.52 | 6.35 | 0.76% |
| Cipla Ltd | 28.83 | 4.43 | 0.88% |
| Torrent Pharmaceuticals Ltd | 63.23 | 15.28 | 0.90% |
Price Comparison
Compare REMLIFE with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Increased Total Retail Holding
In last 3 months, retail holding in the company has increased by 7.87%
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Mar 2024
Jun 2024
Jul 2024
Sep 2024
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
REMLIFE has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Hmm, looks like data is unavailable here. Please come back after some timeNet profit of Remedium Lifecare declined 72.74% to Rs 1.78 crore in the quarter ended September 2024 as against Rs 6.53 crore during the previous quarter ended September 2023. Sales declined 94.65% to Rs 25.08 crore in the quarter ended September 2024 as against Rs 468.57 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales25.08468.57 -95 OPM %17.781.35 - PBDT2.4710.42 -76 PBT2.4610.41 -76 NP1.786.53 -73 Powered by Capital Market - Live
Remedium Lifecare will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live
Remedium Lifecare has postponed the meeting of the Board of Directors which was scheduled to be held on 3 September 2024. The meeting will now be held on 4 September 2024.Powered by Capital Market - Live
Remedium Lifecare will hold a meeting of the Board of Directors of the Company on 3 September 2024.Powered by Capital Market - Live
Net profit of Remedium Lifecare declined 68.76% to Rs 1.64 crore in the quarter ended June 2024 as against Rs 5.25 crore during the previous quarter ended June 2023. Sales declined 76.49% to Rs 77.70 crore in the quarter ended June 2024 as against Rs 330.46 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales77.70330.46 -76 OPM %0.502.20 - PBDT2.287.28 -69 PBT2.277.27 -69 NP1.645.25 -69 Powered by Capital Market - Live
Remedium Lifecare has postponed the meeting of the Board of Directors which was scheduled to be held on 8 August 2024. The meeting will now be held on 14 August 2024.Powered by Capital Market - Live
Remedium Lifecare has entered into a strategic agreement with Angel Partners, UK, effective 29 July 2024, to acquire technology for manufacturing lithium carbonate in India. The company has also signed an annual Supply Agreement with Alfa Chemicals and Solvents, Turkey, effective the same date. Supplies of technical-grade lithium carbonate will commence in the January-March 2025 quarter. The supplies for CY 2025 are valued at USD 20-25 million. Technical-grade lithium carbonate is used in lithium-ion batteries for electric vehicles and portable electronics. Remedium has partnered with various contract manufacturers to produce technical-grade lithium carbonate using the technology from Angel Partners. Powered by Capital Market - Live
Remedium Lifecare Ltd leads losers in ‘B’ group
Ksolves India Ltd, National Peroxide Ltd, Aarti Surfactants Ltd and Jasch Gauging Technologies Ltd are among the other losers in the BSE's 'B' group today, 22 July 2024.Remedium Lifecare Ltd crashed 10.33% to Rs 16.76 at 14:32 IST.The stock was the biggest loser in the BSE's 'B' group.On the BSE, 49.55 lakh shares were traded on the counter so far as against the average daily volumes of 38.14 lakh shares in the past one month.Ksolves India Ltd lost 8.60% to Rs 1104.55. The stock was the second biggest loser in 'B' group.On the BSE, 28586 shares were traded on the counter so far as against the average daily volumes of 6376 shares in the past one month.National Peroxide Ltd tumbled 8.29% to Rs 1059. The stock was the third biggest loser in 'B' group.On the BSE, 19625 shares were traded on the counter so far as against the average daily volumes of 9819 shares in the past one month.Aarti Surfactants Ltd slipped 7.05% to Rs 646.6. The stock was the fourth biggest loser in 'B' group.On the BSE, 3877 shares were traded on the counter so far as against the average daily volumes of 4280 shares in the past one month.Jasch Gauging Technologies Ltd pared 6.37% to Rs 728. The stock was the fifth biggest loser in 'B' group.On the BSE, 11470 shares were traded on the counter so far as against the average daily volumes of 6862 shares in the past one month.Powered by Capital Market - Live
Krebs Biochemicals & Industries Ltd leads gainers in ‘B’ group
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 595.31%, vs industry avg of 9.03%
Increasing Market Share
Over the last 5 years, market share increased from 0% to 1.08%